Executive Search: Biotech, Pharma, MedTech and related nonprofits. We help drive drug development and build mission driven teams. Rare & common disorders.
Boston
Joined November 2013
- Tweets1.7K
- Following2.3K
- Followers428
- Likes4K
Denville Partners retweeted
Q4 and early 2027 hiring continues year-round. Search firms bring comp insight, protect confidentiality, maintain momentum, and negotiate Q1 bonuses, buyouts & equity. Partners through the calendar, not just CVs. #Hiring
Denville Partners retweeted
Current open non-profit opportunities:
VP of Corporate Development and Innovation (ALS)
CEO - rare and ultra rare diseases
COO - rare diseases, operational and finance
We are Denville Partners working at the nexus of nonprofit impact and biotech innovation.
This is big news and outstanding progress for patients. While Rare Disease are now getting long overdue attention, the focus needs to stay on the ecosystem for the long-term.
The FDA today launched the Rare Disease Framework Initiative to reimagine rare disease drug development.
The new framework will adapt aspects of the agency’s long-standing approach designed for larger diseases. It will adopt an optimized, fit-for-purpose framework for rare disease drug development that considers the nuances of a specific disease, patient needs, product type, and attainable evidence. fda.gov/news-events/press-an…
FDA will host a meeting on Oct. 28 at the White Oak campus to collect feedback on the Rare Disease Framework Initiative from patients, disease advocates, industry, and other stakeholders. fda.gov/news-events/fda-meet…
Denville Partners retweeted
Nonprofit CEOs and EDs must lead technology, not just manage it. AI, data and digital fundraising can amplify mission and unlock growth. The wrong hire can cost millions. #ExecutiveSearch #NonprofitLeadership
We love exploring and leveraging new technologies. Instead of debating end of world scenarios, let's take advantage of what is available to make life better for everyone.
A milestone for AI-enabled drug discovery: Insilico’s rentosertib for IPF has entered Phase III, with the first patient dosed. No AI-designed drug has reached approval yet; but the field is moving forward. #Biotech
We are a search firm but technology is an interesting topic. We have had clients openly push back on exploring new technologies that would clearly amplify the org into the future. While uncomfortable, first (early) mover advantage is real. #nonprofit #blockchain #AI
Tomorrow’s nonprofit leaders must lead technology transformation: not simply manage it. AI, data, and digital fundraising can amplify mission when guided by purpose. #NonprofitLeadership #SuccessionPlanning
Denville Partners retweeted
Succession is an opportunity to hire for the future: not replace the past. Seek leaders who scale impact, embrace technology, and build partnerships that move the mission forward. #NonprofitLeadership #SuccessionPlanning
Denville Partners retweeted
Throughout her career caring for children and developing medicines for rare diseases, Nerissa Kreher has met many families searching for a treatment option for their child or loved one.
For many rare and ultra-rare diseases, small patient populations can make studying each disease separately difficult. Basket trials offer another potential path, bringing together people with different diseases that share the same underlying mutation and relevant clinical characteristics.
On Labiotech’s Beyond Biotech podcast, Nerissa discusses why engineered tRNA medicines may be well suited to this approach, the clinical development of AP003, the first tRNA therapeutic to enter clinical trials, and the evidence needed to support future basket trials.
Listen here: podcast.labiotech.eu/1995493…
Denville Partners retweeted
Sometimes a nonprofit’s most promising program belongs outside it. A dedicated spin-out can bring focused capital, speed, and risk tolerance: while the nonprofit retains equity, a seat at the table, and the upside.
Denville Partners retweeted
Today, we announced our Q2 2026 financial results and corporate highlights. Read more in our press release: bit.ly/4zf5dJ0
Denville Partners retweeted
ALS-TDI’s patient-driven model connects patient data, iPSC models and drug discovery. Its copper-complex lead, TDI-1831, is advancing through IND-enabling studies. #ALSResearch #RareDisease
Denville Partners retweeted
What if the money for research reached scientists in weeks instead of years?
American scientists now spend nearly half their time on paperwork. Some grants take two years to approve.
The White House just called this out and asked for the biggest rebuild of science since 1945.
It wants funding to reach researchers directly, young scientists backed early, and people judged on their work, not their place in line. It also says AI will change how discovery happens, but the best models will stall inside institutions built for the last century.
This is the model onchain science already runs. A scientist with an agent fleet and an onchain treasury can run programs that once needed a whole institution.
The funding comes straight from the people who want the work done. Every step is recorded in the open. The scientist sets the direction, and the infrastructure carries it out.
The report is describing a future we are already building at Bio.
Denville Partners retweeted
Call for Research Proposals! Each year, the ULF welcomes researchers from around the world to submit their research project proposals for funding consideration. Applications are now being accepted through August 12, 2026. For more details, visit: ulf.org/research/research-gr…
Denville Partners retweeted
Excited to kick off our #CAMP4Fireside Series to highlight the people behind CAMP4. Hear from our CEO, Josh Mandel-Brehm, as he shares a glimpse into what’s ahead. Watch the video, and learn more about our mission here: camp4tx.com/
Denville Partners retweeted
Biotech startups offer a 'resilience dividend.' Even if a venture fails, the experience of building from scratch is resume gold. These unique skills make it a low-risk career move in the long run.
#BiotechCareers #Resilience #DenvillePartners #Leadership
Denville Partners retweeted
Columnist Patrick Moeschen invites readers to join the newly relaunched Muscular Dystrophy News Today Forums, where a community is growing. buff.ly/FyFBeli
#musculardystrophynews #musculardystrophy #musculardystrophycommunity #livingwithMD
ALT Banner for Patrick Moeschen's column, "Muscle Memoirs: LGMD Experience"
Denville Partners retweeted
Today we announced our Q1 2026 financial results highlighting progress across our pipeline. See the press release here bit.ly/3RxC4Y5
Would you hire you ??
Tough conversations in full transparency:
We are extremely fortunate to have the opportunity to work on very senior level high impact positions.
We are hired to ensure that our client hires the best candidate possible.
Since we are so proactive in our approach, we often end up speaking with multiple highly qualified passionate human beings.
Some or are more qualified than others, and some are better fit than others.
If we are doing our work right, we have to make some very challenging decisions about who and who we don’t present
Telling someone that we have decided not to present their credentials can be a challenging conversation. After all, we are only a search firm, right?
There is typically one of two reactions.
I will let you guess what they are.
Some of these folks become clients for life. The others…….
However, I have found that one question often helps us level set in that question is:
If you were the hiring manager for this position, would you hire you?
Be honest, would you?